PCRX Pacira BioSciences Inc

$PCRX Pacira BioSciences, maker of non-opioid pain drugs EXPAREL and ZILRETTA, agreed to be bought by Viatris for $36.50 a share in cash, about $1.65B of equity value, in a tender offer its board unanimously backs. That is about 2.2x the $735M-$760M of revenue Pacira guides to for 2026. Holders forgo Phase 2 Part A data on PCRX-201, its knee gene therapy, due by end of 2026; Viatris expects the deal to be immediately accretive. Pacira owes a $62M fee if it takes a superior bid. Tender needs a majority and HSR clearance; close seen by end-2026.

$PCRX is seeing a strong reaction on M&A / acquisition following a PR Newswire release. Viatris agreed to acquire Pacira BioSciences for $1.65 billion ($36.50/share) to gain non-opioid pain therapy products EXPAREL and ZILRETTA, expected to close by end of 2026. RTPR pushed this release out to users at 7:45:00 AM ET

$PCRX own this for a while now, boring stock, trades sideways, no up no down, dissapointed

$PCRX Long — $36.50 in cash is the hardest floor in biopharma, and the last 0.3% is free money for anyone who can read a filing calendar. The 21% of the float that was short Pacira now covers at a price set by two corporate lawyers, not by the market.

$PCRX Viatris is buying Pacira for 36.50 a share in cash, a 1.65 billion dollar deal announced this morning. The premium is 44.8 percent over Wednesday's 25.20 close. Shares are up about 44 percent to near 36.30, pacing the largest single-day gain on record (Barron's via Dow Jones Market Data). Trading a hair below the offer price is the market's verdict on a topping bid. Pacira brings real numbers: about 746 million in LTM revenue with adjusted EBITDA near 177 million, on Exparel and Zilretta product sales of 575.1 million and 116.6 million last year (per Viatris and Reuters). Viatris says the deal is immediately accretive with minimal impact on its leverage. One level down, this reads as rescue as much as bid. Pacira was in a multiyear decline and cut its sales outlook in August. Oppenheimer called the premium full price. The deal is expected to close by year end.

$PCRX +44% this morning on a cash buyout: Viatris is paying 36.50 per share, ~1.65B total. My screener lit up on it: volume surge (~151x the 20-day average, projected), yearly-high breakout, RSI 85 overbought. At 10:25 ET it sat at 36.30, so ~0.5% under the deal price. Funny thing: in a cash deal, none of those technical signals really mean much anymore. The price is pinned to 36.50 unless the deal breaks or someone bids higher. Old 52-week high was 27.66, so the premium is real. $VTRS about -2% on the news. Anyone playing the spread, or is 0.5% not worth the deal risk?